Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · IEX Real-Time Price · USD
7.71
+0.04 (0.52%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Travere Therapeutics Market Cap
Travere Therapeutics has a market cap or net worth of $593.57 million as of March 28, 2024. Its market cap has decreased by -54.64% in one year.
Market Cap
593.57M
Enterprise Value
431.50M
1-Year Change
-54.64%
Ranking
Category
Stock Price
$7.71
Market Cap Chart
Since December 31, 2012, Travere Therapeutics's market cap has increased from $40.40M to $593.57M, an increase of 1,369.23%. That is a compound annual growth rate of 27.00%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Mar 27, 2024 | 583.70M | 1.32% |
Mar 26, 2024 | 576.10M | -1.56% |
Mar 25, 2024 | 585.20M | -2.42% |
Mar 22, 2024 | 599.70M | -2.58% |
Mar 21, 2024 | 615.60M | 4.25% |
Mar 20, 2024 | 590.50M | 3.74% |
Mar 19, 2024 | 569.20M | 4.17% |
Mar 18, 2024 | 546.40M | -4.14% |
Mar 15, 2024 | 570.00M | -0.52% |
Mar 14, 2024 | 573.00M | -7.61% |
Mar 13, 2024 | 620.20M | 5.15% |
Mar 12, 2024 | 589.80M | -2.99% |
Mar 11, 2024 | 608.00M | -7.74% |
Mar 8, 2024 | 659.00M | -0.57% |
Mar 7, 2024 | 662.80M | 1.16% |
Mar 6, 2024 | 655.20M | 7.09% |
Mar 5, 2024 | 611.80M | -1.83% |
Mar 4, 2024 | 623.20M | 4.06% |
Mar 1, 2024 | 598.90M | 4.10% |
Feb 29, 2024 | 575.30M | -2.95% |
Feb 28, 2024 | 592.80M | -6.26% |
Feb 27, 2024 | 632.40M | 3.62% |
Feb 26, 2024 | 610.30M | 1.01% |
Feb 23, 2024 | 604.20M | 1.02% |
Feb 22, 2024 | 598.10M | -0.27% |
View and export this data all the way back to 2012.
Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
InnovAge Holding | 589.80M |
The Pennant Group | 588.55M |
Absci | 587.61M |
Calliditas Therapeutics AB (publ) | 586.37M |
Taysha Gene Therapies | 585.37M |
ArriVent BioPharma | 575.22M |
ALX Oncology Holdings | 574.24M |
AnaptysBio | 572.20M |